By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – In the midst of reporting soft first-quarter earnings results that failed to meet Wall Street expectations, Qiagen officials today continued to be optimistic that the company will meet its full-year 2011 guidance with a bounceback in its human papillomavirus business, new revenue streams from its pending Cellestis acquisition, and the development of new assays and platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.